Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Empresa
Empresa
Nuestra historia
Nuestro equipo
Carreras
Socios
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Acceso
Asuntos médicos
Acceso de pacientes
Póngase en contacto con Asuntos Médicos
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Recursos
Recursos
En las noticias
Comunicados de prensa
Recursos para pacientes
Preguntas frecuentes
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Inversores
Inversores
Descripción general del inversor
Información financiera
Eventos
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children.
Other Articles & Publications
New England Journal of Medicine
June 2, 2022
,
RTS,S Clinical Trials Partnership, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy.
Other Articles & Publications
Vaccine
June 2, 2022
,
Mo, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial.
Other Articles & Publications
The Lancet Infectious Diseases
June 2, 2022
,
Asante, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants.